Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

688

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

20 mg(2#)/day, PO, daily

DRUG

Placebo

2#/day, PO, daily

Trial Locations (17)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

510000

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

510010

RECRUITING

Guangdong Women and Children Hospital, Guangzhou

RECRUITING

Guangzhou Army General Hospital, Guangzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

510120

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

510180

RECRUITING

Guangzhou Women and Children Hospital, Guangzhou

516000

RECRUITING

The third people's Hospital of Huizhou, Huizhou

Unknown

RECRUITING

Xinjiang Medical School Cancer Center, Xinjiang

RECRUITING

Dongguan People's Hospital, Dongguan

RECRUITING

Foshan First People's Hospital, Foshan

RECRUITING

The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

RECRUITING

Lian Jiang People's Hospital, Lianjiang

RECRUITING

The Third Hospital of Nanchang, Nanchang

RECRUITING

The Second People's Hospital of Shenzhen, Shenzhen

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER